Drugs for Nonseminomatous Germ Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 30)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Cisplatin |
Approved |
Phase 3 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
2 |
|
Bleomycin |
Approved, Investigational |
Phase 3 |
|
9041-93-4, 11056-06-7 |
5360373 |
Synonyms:
Almirall brand OF bleomycin sulfate
Bellon brand OF bleomycin sulfate
Bellon, bléomycine
Blanoxan
Blenoxane
Bleo
Bleo cell
Bleo-cell
BLEOcell
Bleocin
BLEO-KYOWA
Bleolem
Bleomicin
Bleomicina
Bleomicina [INN-Spanish]
Bleomycin
Bleomycin a(2)
Bleomycin a2
Bleomycin b(2)
Bleomycin b2
BLEOMYCIN HYDROCHLORIDE
|
Bleomycin sulfate
Bleomycin sulphate
Bleomycine
Bleomycine [INN-French]
Bléomycine bellon
Bleomycins
Bleomycinum
Bleomycinum [INN-Latin]
Bleomycinum mack
BLM
Bristol myers squibb brand OF bleomycin sulfate
Bristol-myers squibb brand OF bleomycin sulfate
Bull brand OF bleomycin sulfate
Cell pharm brand OF bleomycin sulfate
Lemery brand OF bleomycin sulfate
Lundbeck brand OF bleomycin sulfate
Mack brand OF bleomycin sulfate
Mack, bleomycinum
NSC-125066
Sulfate, bleomycin
|
|
3 |
|
Etoposide |
Approved |
Phase 3 |
|
33419-42-0 |
36462 |
Synonyms:
(-)-Etoposide
(−)-ETOPOSIDE
(-)-etoposide|Etopophos®|Toposar®|trans-etoposide|VePesid®|VP 16-213|VP-16
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
alpha-D-Glucopyranosyl isomer etoposide
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
Celltop
Demethyl epipodophyllotoxin ethylidine glucoside
Eposide
Eposin
Eto gry
Eto-gry
Etomedac
Etopophos
Etopos
ETOPOSIDE
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
|
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
Lastet
Lemery brand OF etoposide
Medac brand OF etoposide
Novartis brand OF etoposide
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Riboposid
Ribosepharm brand OF etoposide
Sanfer brand OF etoposide
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Teva, etoposide
Toposar
trans-Etoposide
Vepesid
Vepesid J
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16-213
VP-16
VP-16-213
Zuyeyidal
|
|
4 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 3 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
5 |
|
Ifosfamide |
Approved |
Phase 3 |
|
3778-73-2 |
3690 |
Synonyms:
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Asta Z 4942
Holoxan
Ifex
Ifosfamid
Ifosfamida
IFOSFAMIDE
Ifosfamide sterile
Ifosfamidum
Ifosphamide
Ifsofamide
Iphosphamid
|
Iphosphamide
I-phosphamide
Iso endoxan
Iso-endoxan
Isofosfamide
Isophosphamide
Isosfamide
MITOXANA
MJF-9325
NSC-109724
Z-4942
|
|
6 |
|
Oxaliplatin |
Approved, Investigational |
Phase 3 |
|
61825-94-3 |
43805 11947679 6857599 |
Synonyms:
ACT 078
ACT-078
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatine
Elplat
Foloxatine
JM-83
L-OHP
L-OHP CPD
MBP-426 (LIPOSOMAL OXALIPLATIN)
NSC-266046
Oxalatoplatin
|
Oxalatoplatinum
Oxaliplatin
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
RP-54780
SR-96669
Transplatin
|
|
7 |
|
Palifosfamide |
Investigational |
Phase 3 |
|
31645-39-3 |
100427 |
Synonyms:
Ifosfamide mustard
Ifosforamide mustard
IPAM
Iphosphoramide mustard
IPM
Isophosphamide mustard
Isophosphoramide mustard
N,N'-BIS-(2-CHLOROETHYL)PHOSPHORIC ACID
|
N,N'-di-(2-chloroethyl)phosphorodiamidic acid
NN'-Bis-(2-chloroethyl)phosphate
NN'-Bis-(2-chloroethyl)phosphoric acid
NSC-297900
Palifosfamide
Palifosfamide-tris
ZIO-201
Zio-201isophosphamide mustard
|
|
8 |
|
Alkylating Agents |
|
Phase 3 |
|
|
|
9 |
|
Antineoplastic Agents, Alkylating |
|
Phase 3 |
|
|
|
10 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
11 |
|
Albumin-Bound Paclitaxel |
|
Phase 3 |
|
|
|
12 |
|
Etoposide phosphate |
|
Phase 3 |
|
|
16760419 |
Synonyms:
{4-[16-({7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-D][1,3]dioxin-6-yl}oxy)-12-oxo-4,6,13-trioxatetracyclo[7.7.0.0,.0,]hexadeca-1,3(7),8-trien-10-yl]-2,6-dimethoxyphenoxy}phosphonate
BMY-40481
ETOPOPHOS
ETOPOPHOS PRESERVATIVE FREE
|
ETOPOSIDE PHOSPHATE
Etoposide phosphoric acid
VP16
VP-16
|
|
13 |
|
Antimitotic Agents |
|
Phase 3 |
|
|
|
14 |
|
Tubulin Modulators |
|
Phase 3 |
|
|
|
15 |
|
Antibiotics, Antitubercular |
|
Phase 3 |
|
|
|
16 |
|
Gemcitabine |
Approved |
Phase 2 |
|
95058-81-4, 122111-03-9 |
60750 |
Synonyms:
2',2'-DFDC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
DDFC
DFDC
DFdCyd
Gemcin
GEMCITABIN
Gemcitabina
Gemcitabina [INN-Spanish]
GEMCITABINE
GEMCITABINE HCL
|
Gemcitabine hydrochloride
gemcitabine hydrochloride|Gemzar®
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
GEO
INFUGEM
LY188011
LY-188011
LY188011 HYDROCHLORIDE
LY-188011 HYDROCHLORIDE
NSC-613327
|
|
17 |
|
Mechlorethamine |
Approved, Investigational |
Phase 2 |
|
51-75-2 |
4033 |
Synonyms:
2,2'-Dichloro-N-methyldiethylamine
b,Beta'-dichlorodiethyl-N-methylamine
beta,Beta'-dichlorodiethyl-N-methylamine
BIS (2-CHLOROETHYL) METHYLAMINE
Bis(2-chloroethyl)methylamine
Bis(b-chloroethyl)methylamine
Bis(beta-chloroethyl)methylamine
Bis(β-chloroethyl)methylamine
Caryolysine
Chlorethazine
Chlormethine
Chlormethinum
Cloramin
Clormetina
Embichin
HN2
HN-2
Hydrochloride N-oxide, mechlorethamine
Hydrochloride, mechlorethamine
MBA
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethamine hydrochloride N oxide
Mechlorethamine hydrochloride N-oxide
Mechlorethamine N oxide
Mechlorethamine N-oxide
Mechlorethamine oxide
Mechloroethamine
Mecloretamina
|
Merck brand OF mechlorethamine hydrochloride
Merck frosst brand OF mechlorethamine hydrochloride
Methylbis(2-chloroethyl)amine
Methylbis(b-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methylbis(β-chloroethyl)amine
Methylchlorethamine
Mitomen
Mustargen
Mustine
Nitrogen mustard
Nitrogen mustard N oxide
Nitrogen mustard N-oxide
NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE
Nitrogranulogen
Nitromin
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(b-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis(β-chloroethyl)amine
N-Oxide, mechlorethamine hydrochloride
N-Oxide, nitrogen mustard
NSC 762
NSC-10107
NSC-128663
NSC-762
Β,beta'-dichlorodiethyl-N-methylamine
β,β'-dichlorodiethyl-N-methylamine
|
|
18 |
|
Durvalumab |
Approved, Investigational |
Phase 2 |
|
1428935-60-7 |
|
Synonyms:
|
19 |
|
Tremelimumab |
Approved, Investigational |
Phase 2 |
|
745013-59-6 |
|
Synonyms:
CP-675,206
CP-675|CP-675,206|CP-675206|ticilimumab
CP-675206
|
TICILIMUMAB
TREMELIMUMAB
TREMELIMUMAB (GENETICAL RECOMBINATION)
|
|
20 |
|
Fludarabine |
Approved |
Phase 2 |
|
75607-67-9, 21679-14-1 |
30751 657237 |
Synonyms:
2-F-ARAA
2-F-Ara-A|CCRIS 3382|F-Ara-A|Fludara®
2F-Ara-AMP
2-fluoro ARA-A
2-Fluoroadenine arabinoside 5'-monophosphate
2-Fluoroadenine arabinoside 5'-monophosphoric acid
2-Fluoro-ara AMP
2-FLUORO-ARA-A
9 beta-D-Arabinofuranosyl-2-fluoroadenine monophosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-Β-arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-Β-arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
|
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-Β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
Beneflur
FAMP
FaraAMP
F-Ara-AMP
Fludara
Fludarabina
FLUDARABINE
Fludarabine 5'-monophosphate
Fludarabine 5'-monophosphoric acid
Fludarabine monophosphate
Fludarabine monophosphoric acid
Fludarabine phosphate
Fludarabine phosphoric acid
Fludarabinum
Fludura
Fluoro-ara-AMP
NSC-312887
NSC-328002
OFORTA
|
|
21 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
22 |
|
Brentuximab vedotin |
Approved, Investigational |
Phase 2 |
|
914088-09-8 |
|
Synonyms:
124490327
ADCETRIS
Adcetris®|anti-CD30 ADC SGN-35|SGN 35
Brentuximab
BRENTUXIMAB VEDOTIN
Brentuximab vedotin brentuximab
|
Brentuximab vedotina
CAC10-VCMMAE
Moab, chimeric, SGN-30, to CD30 antigen
Monoclonal antibody SGN-30
SGN-35
|
|
23 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
24 |
|
Antiviral Agents |
|
Phase 2 |
|
|
|
25 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
26 |
|
Antimetabolites |
|
Phase 2 |
|
|
|
27 |
|
Antirheumatic Agents |
|
Phase 2 |
|
|
|
28 |
|
Immunosuppressive Agents |
|
Phase 2 |
|
|
|
29 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
30 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show all 13)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors |
Active, not recruiting |
NCT00104676 |
Phase 3 |
cisplatin;etoposide;ifosfamide;oxaliplatin;paclitaxel |
2 |
A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors |
Unknown status |
NCT02115165 |
Phase 2 |
Cabazitaxel |
3 |
A Prospective Multicenter Phase II Trial of Gemcitabine, Cisplatin, and Ifosfamide (GIP) in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors (NSGCT) and a Predicted Favorable Prognosis |
Unknown status |
NCT00127049 |
Phase 2 |
gemcitabine, ifosfamide, cisplatin, G-CSF |
4 |
A Prospective,Multicenter, Phase II Study to Evaluate the Contribution of the Imaging TEP to the Expression of intégrines αvβ3 for the Characterization of the Residual Masses of Non-seminoma Tumors at the End of Chemotherapy |
Completed |
NCT02317393 |
Phase 2 |
|
5 |
A Treatment Strategy of the Use of 1st Line Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Based on Tumor Marker Decline: A Phase II Trial of Paclitaxel, Ifosfamid and Cisplatin Regimen. |
Completed |
NCT02414685 |
Phase 2 |
Paclitaxel;Ifosfamide;Cisplatin |
6 |
A Single-arm, Phase II Study of Durvalumab (MEDI4736) and Tremelimumab for Relapsed/Refractory Germ Cell Tumors |
Active, not recruiting |
NCT03158064 |
Phase 2 |
Durvalumab;Tremelimumab |
7 |
Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Patients With CD30+ Nonseminomatous Germ Cell Tumors (NSGCT) |
Not yet recruiting |
NCT05634785 |
Phase 2 |
Cyclophosphamid;Fludarabine |
8 |
Randomized Phase II Trial Evaluating Compliance With Monitoring Conducted Either by a Hospital-based Physician in Person or by a Nurse in Remote Monitoring |
Not yet recruiting |
NCT05500391 |
Phase 2 |
|
9 |
A Multicenter Phase II Study of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors |
Terminated |
NCT02689219 |
Phase 2 |
Brentuximab Vedotin |
10 |
A Phase II Single-Arm Multi-Center Trial Evaluating the Efficacy of Pembrolizumab in the Treatment of Subjects With Incurable Platinum-Refractory Germ Cell Tumors: Hoosier Cancer Research Network GU14-206 |
Terminated |
NCT02499952 |
Phase 2 |
Pembrolizumab |
11 |
Assessment of the Utility of CT Follow Up in the Long Term Follow Up of Patients With Metastatic Non Seminomatous Germ Cell Tumour (NSGCT) |
Unknown status |
NCT00553371 |
|
|
12 |
Correlation of Histopathology, Immunohistochemistry and Quantitative Radiology With Outcome in Early Stage Nonseminomatous Germ Cell Tumor |
Completed |
NCT00003800 |
|
|
13 |
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials |
Recruiting |
NCT05108298 |
Early Phase 1 |
|
|